Skip to main content
. Author manuscript; available in PMC: 2013 Jul 31.
Published in final edited form as: J Hepatol. 2010 Dec 15;55(2):315–321. doi: 10.1016/j.jhep.2010.11.020

Table 6.

Change in MAP from baseline to EOT for terlipressin and placebo non-responders and responders.

Treatment n Baseline EOT Change from baseline
Mean (SD) Mean (SD) Mean change* (SE) p vs. baseline Difference (SE) p vs. non-responders
Terlipressin
 Responders 19 72.8 (11.6) 80.7 (7.9) 7.3 (3.0) 0.017 8.3 (3.6) 0.025
 Non-responders 37 76.9 (11.3) 76.5 (12.4) −1.0 (2.2) 0.641
Placebo
 Responders 7 79.0 (13.9) 83.1 (6.7) 3.1 (5.1) 0.547 8.8 (5.4) 0.110
 Non-responders 48 77.0 (13.8) 71.9 (11.2) −5.7 (2.0) 0.006
*

Least squares mean.

EOT: end of treatment, SD: standard deviation, SE: standard error.